ALK and non-small cell lung carcinoma: In conclusion, this validation study including patients from two large academic centers demonstrated that ALK-BPI is a novel prognostic tool for TKI-treated ALK+ NSCLC patients with BM, and thus represents a practical method for refined patient stratification in daily clinical practice.